Sanofi Fights To Hang On To Eloxatin

By Sam Schulz

Law360, New York (June 15, 2007, 12:00 AM ET) -- In a move to defend its claim to the U.S. market, Sanofi-Aventis U.S. LLC sued Sandoz Inc. Thursday for allegedly infringing a patent for its popular colon cancer drug, which a handful of other countries have already rejected.

The New Jersey district court case says that Sandoz filed an Abbreviated New Drug Application with the Food and Drug Administration for a generic version of oxaliplatin, which Sanofi holds the patents for and markets as Eloxatin.

According to the complaint, Sandoz's ANDA called the Sanofi patents, U.S....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles